Detailed Narrative
Industry Landscape and Strategic Focus
The diagnostics industry continues to see stable demand, with growth increasingly driven by specialty diagnostics, preventive healthcare, and complex testing. Metropolis emphasizes accuracy, depth of insight, and precision-led decision-making, aligning with shifting clinician and patient awareness. The Union Budget's focus on healthcare infrastructure and workforce development is expected to create new opportunities, especially in smaller markets. The sector is also consolidating, with a renewed focus on long-term growth and strong economics rather than discount-led revenue.
Q3 FY26 Performance Highlights
Metropolis Healthcare reported strong Q3 FY26 results, with group revenues growing 26% year-on-year and 9-month revenues increasing by 24%. Organic revenue growth remained healthy at 15% for the quarter and 13% for the 9 months, supported by 9% patient volume growth and 8% test volume growth. The organic EBITDA margin expanded by 280 basis points year-on-year to 25%, driven by material cost efficiencies and operating leverage. Group PAT, excluding exceptional item📎s, grew 63% year-on-year to INR 51 crores, with a PAT margin of 12.6%.
Acquisitions and Integration Progress
Recent acquisitions, including Core Diagnostics, DAPIC (Dehradun), Scientific Pathology (Agra), and Ambika Diagnostics (Kolhapur), are progressing well and are integrated into the Metropolis system. Core Diagnostics' Q3 margins were impacted by a 3-month delay in the launch of its genomics platform, which began in January 2026. Management expects a meaningful improvement in Core's gross margin and a high single-digit EBITDA margin by Q4 FY26. Smaller acquisitions are performing as expected, delivering margins better than the group average, with overall synergy benefits anticipated by year-end.
Genomics and AI Initiatives
A key milestone was the launch of the Center of Genomics in Delhi, integrating Core Diagnostics as a national reference hub for advanced molecular testing. This platform aims to deliver clinically-actionable genomic insights across oncology, reproductive health, and inherited disorders, a category expected to grow rapidly. In AI, Metropolis is focusing on selective high-impact use cases like enhanced test interpretation and quality monitoring, rather than broad-based deployment. The company also secured its first patent for a system focused on monitoring and managing TB-related infections.
Capital Allocation and Shareholder Returns
The company remains net debt-free with current cash reserves of INR 127 crores. Estimated capex for FY26 is between INR 55-60 crores, with approximately INR 40 crores spent in the first 9 months, primarily for network expansion, IT upgrades, and high-end equipment. The Board of Directors approved a bonus issue in the ratio of 3:1 (3 fully paid-up equity shares for every 1 existing share), subject to necessary approvals. This bonus issue reflects the company's strong financial position and confidence in its long-term growth prospects.
Regulatory Environment and Pricing Strategy
Management noted that the healthcare and diagnostics sector is predominantly domestic, making it largely neutral to global tariff actions and trade policies. The recently announced Union Budget reinforces a long-term policy commitment to expanding healthcare access and quality. Regarding pricing, while there was a marginal benefit from GST changes, the company delayed its annual price revision in January to pass benefits to customers. Management believes the market is conducive for price increases and will decide on implementation at an appropriate time⏳.